News Agency News Aggregator Journalist/Editor Broking House Others
#Glenmark explanation on query and how it went... Never forget bigger frames... Takes trades in direction of larger frames you will have better probability...
Cox & Kings, Delta Corp, Eicher Motors, Excel Indus, GAIL, Glenmark Pharmaceuticals, Graphite India, HEG, IDBI Bank, Vodafone Idea, Jubilant Indus, L&T Finance Hold, Mindtree, Oil India, Tata Elxsi,TVS Motor Co also featured among the stocks that touched their 52-week lows on NSE
#BrokerageRadar | MACQUARIE ON GLENMARK
#GLENMARK fallen again... yesterday post on weekly correlation with smaller frame will also help you @wackyonlyanil
▶ Lupin, Glenmark, RIL likely to be in limelight today - DNA India: Lupin, Glenmark, RIL likely to be in limelight today DNA India Bull market as the index has taken a good support in the last trading session and it has confirmed higher tops and… GOOGLE
GLENMARK - Shareholding for the Period Ended June 30, 2019
Buy above- HDFCB (2444), SBIN(367), GLENMARK (461), POWER GRID (212), WIPRO(264.5), TATASTEEL(483), JSPL(144C), BPCL SHORT below- AXISB(742), BAJAJAUTO(2648), COALI(227), PNB (70.7), TATAPOWER (65.5), PIDILIT(1173), UBI(74).
Cipla is the latest co to enter into China, forms JV w/ Jiangsu Acebright, focusing on respiratory drugs. Other cos with presence there: Sun, Dr Reddys, Natco, Cadila, Glenmark
Nifty Pharma index rose 1% amid buying interest seen in Sun Pharma and Piramal Enterprises. Dr. Reddy’s, Divi’s Lab, and Lupin also gained in today’s session. On the flip side, Aurobindo Pharma slipped 2%, and Glenmark, Biocon, Cipla and Cadila also fell in today’s trade.
GLENMARK - Statement Of Investor Complaints For The Quarter Ended June 2019
Glenmark Pharmaceuticals (down 1.75 per cent), Aurobindo Pharma (down 1.58 per cent) and Cadila Healthcare (down 1.48 per cent) were trading with losses.
Glenmark has received USFDA approval for its drug Ranolazine tablets for treatment of chronic angina.
#GlenmarkPharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: #PrabhudasLilladher Net Sales are expected to increase by 5.6 percent Y-o-Y (down 11 percent Q-o-Q) to Rs. 2,247.9 crore, according to Prabhudas Lilladher.
#OnCNBCTV18 | Amey Chalke, @hdfcsec says expect improvement in @drreddys's #US business driven by 30 launches; Have a target of Rs 3,300/sh for DRL & expect a soft Q1 for Glenmark on account of restructuring #1QWithCNBCTV18 @latha_venkatesh @_soniashenoy @ekta_batra
Shares of Sun Pharmaceutical Industries (up 0.60 per cent), Lupin (up 0.45 per cent), Biocon (up 0.12 per cent), Glenmark Pharmaceuticals (up 0.03 per cent) were trading higher.
Buy Glenmark Sl 448 CMP 454